Pfizer EH segment sales recorded a decline of 14% (down 12% operationally) to $5.23 billion. Excluding HIS revenues, EH sales declined 7%. EH revenues were hurt by the loss of exclusivity and associated generic competition for products like Pristiq (generic versions launched in the U.S. in Mar 2017), Vfend, Zyvox, Celebrex, Lyrica; lower revenues from legacy Hospira products and divesture of HIS. However, in the EH business, biosimilars and emerging markets did well in the quarter.